Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862861 | 1.00 | PRCP (0.50) | PRCPDPP7TLR2NOS2NOS3 | |
| SCHEMBL809691 | 1.00 | PRCP (0.50) | PRCPDPP7TLR2NOS2NOS3 | |
| SCHEMBL1837318 | 0.94 | PRCP (0.45) | PRCPDPP7TLR2NOS2NOS3 | |
| SCHEMBL4724631 | 0.90 | PRCP (0.46) | PRCPDPP7TLR2NOS2NOS3 | |
| SCHEMBL5794043 | 0.87 | PRCP (0.51) | PRCPDPP7TLR2NOS2NOS3 | |
| SCHEMBL17375664 | 0.87 | PRCP (0.51) | PRCPDPP7TLR2NOS2NOS3 | |
| SCHEMBL17375666 | 0.87 | PRCP (0.51) | PRCPDPP7TLR2NOS2NOS3 | |
| Hydrochloric Acid SCHEMBL28132269 | 0.85 | PRCP (0.50) | PRCPDPP7TLR2NOS2NOS3 | |
| SCHEMBL23892030 | 0.81 | NOS2 (0.47) | PRCPDPP7TLR2NOS2NOS3 | |
| SCHEMBL4615012 | 0.81 | PRCP (0.47) | PRCPDPP7TLR2NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022106611-A1 | NOVEL COMPOSITIONS OF BETA-LACTAM COMPOUNDS | XELLIA PHARMACEUTICALS APS (DK) | 2022-05-27 | — | — | WO | claimed |
| WO-2022106630-A1 | STABLE FORMULATIONS COMPRISING PIPERACILLIN AND/OR TAZOBACTAM | XELLIA PHARMACEUTICALS APS (DK) | 2022-05-27 | — | — | WO | claimed |
| EP-1570840-B1 | Topical composition comprising n-acetylamino acids | YU RUEY J (US) | 2009-04-01 | — | — | EP | claimed |
| EP-1843661-A4 | COMPOSITIONS COMPRISING O-ACETYLSALICYL DERIVATIVES OF AMINOCARBOHYDRATES AND AMINO ACIDS | YU RUEY J (US) | 2009-01-14 | — | — | EP | claimed |
| US-20080214649-A1 | Compositions and Therapeutic Use of N-Acetyl Aldosamines and N-Acetylamino Acids | YU RUEY J | 2008-09-04 | — | — | US | claimed |
| US-20080032937-A1 | Bioavailability and Improved Delivery of Alkaline Pharmaceutical Drugs | YU RUEY J | 2008-02-07 | — | — | US | claimed |
| EP-1843661-A2 | COMPOSITIONS COMPRISING O-ACETYLSALICYL DERIVATIVES OF AMINOCARBOHYDRATES AND AMINO ACIDS | Yu, Ruey J., Dr. (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2006084174-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ALKALINE PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2006-08-10 | — | — | WO | claimed |
| US-20060166901-A1 | Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids | YU RUEY J | 2006-07-27 | — | — | US | claimed |
| WO-2006074114-A2 | COMPOSITIONS COMPRISING O-ACETYLSALICYL DERIVATIVES OF AMINOCARBOHYDRATES AND AMINO ACIDS | YU RUEY J (US) | 2006-07-13 | — | — | WO | claimed |
| EP-1660507-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20060063827-A1 | Systemic administration of therapeutic amino acids and N-acetylamino acids | YU RUEY J | 2006-03-23 | — | — | US | claimed |
| EP-1601366-A1 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ALKALINE PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-07 | — | — | EP | claimed |
| US-20050196418-A1 | Bioavailability and improved delivery of alkaline pharmaceutical drugs | YU RUEY J (US) | 2005-09-08 | — | — | US | claimed |
| WO-2005021558-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | claimed |
| US-20040214215-A1 | Bioavailability and improved delivery of alkaline pharmaceutical drugs | YU RUEY J (US) | 2004-10-28 | — | — | US | claimed |
| WO-2004080468-A1 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ALKALINE PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-23 | — | — | WO | claimed |
| US-20040147452-A1 | Non-amphoteric glutathione derivative compositions for tropical application | YU RUEY J | 2004-07-29 | — | — | US | claimed |
| WO-2004010968-A1 | NON-AMPHOTERIC GLUTATHIONE DERIVATIVE COMPOSITIONS FOR TOPICAL APPLICATION | YU RUEY J (US) | 2004-02-05 | — | — | WO | claimed |